miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 10, 2025

RadNet raises 2025 revenue guidance as advanced imaging volumes and digital health drive growth

View original at seekingalpha.com
RadNet raises 2025 revenue guidance as advanced imaging volumes and digital health drive growth Earnings Call Insights: RadNet, Inc. (RDNT) Q3 2025 MANAGEMENT VIEW * CEO Howard Berger opened by stating, "I am very pleased with the performance in the third quarter…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Q3 2025 revenue and adjusted EBITDA were both quarterly records and exceeded internal budgets set at the beginning of 2025.

    80% confidence
  • iCAD contributed approximately $3.9 million in revenue during Q3 2025.

    80% confidence
  • TechLive rollout should be substantially complete by the end of 2025, and has reduced exam closure hours by about 42% relative to last year.

    80% confidence
  • Advanced imaging volumes increased 13.0% on an aggregate basis and 9.9% on a same-center basis, driven by equipment upgrades, AI-driven scheduling, capacity expansion, and shift from hospital to ambulatory imaging.

    80% confidence
  • 2026 Medicare reimbursement changes will benefit RadNet with approximately $4-5 million revenue uplift on roughly $2 billion of revenue.

    80% confidence
  • Labor markets for radiology technologists remain challenging but have stabilized, and RadNet is seeing increasing inbound calls from health systems for partnership opportunities.

    80% confidence
  • Cash balance as of September 30, 2025 was $804.7 million with net debt to adjusted EBITDA ratio of approximately 1.0.

    80% confidence
  • Virtual radiology is an inevitability, and DeepHealth serves as a platform to bundle and integrate multiple AI modules for both internal and external customers.

    80% confidence
  • EBCD payer adoption discussions are progressing positively with increasing traction, though large payers move slowly.

    80% confidence
  • AI revenue within Digital Health, inclusive of iCAD revenue from ProFound AI and Deep Health solutions, increased 112% from Q3 2024.

    80% confidence
  • Digital Health revenue increased 51.6% from Q3 2024, partially due to iCAD's revenue contribution since July 17 acquisition.

    80% confidence
  • See-Mode's thyroid ultrasound technology achieved a 30% reduction in scan time across 240+ centers.

    80% confidence
  • PET/CT growth is driven by PSMA and amyloid brain studies, which now make up 20% of PET/CT volume.

    80% confidence
  • RadNet needs more sales personnel post-iCAD acquisition, and margin expansion will increasingly be driven by digital health tools.

    80% confidence
  • Aggregate MRI volume increased 14.8%, CT volume increased 9.4%, and PET/CT volume increased 21.1% from Q3 2024.

    80% confidence
  • Total company revenue increased 13.4% and adjusted EBITDA increased 15.2% relative to Q3 2024, resulting in a 26 basis point improvement in adjusted EBITDA margins.

    80% confidence
  • Adjusted EBITDA margins increased by 26 basis points from 16% to 16.2% year-over-year.

    80% confidence
  • Exposure to Medicaid and health insurance exchanges is minimal, reducing risk from policy changes.

    80% confidence
  • RadNet increased imaging center revenue guidance by $50 million at the low end and $30 million at the high end, and increased adjusted EBITDA guidance by $5 million at both ends.

    80% confidence
  • EBCD AI revenue rose 28.7% year-over-year.

    80% confidence
  • RadNet operates 407 centers as of September 30, 2025, with one new center opened during Q3 and 4.9% total same-center procedure volume growth.

    80% confidence
  • DSOs (Days Sales Outstanding) reduced to 31.9 days, the lowest historical level for RadNet.

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
RadNet raises 2025 revenue guidance as advanced imaging volumes and digital health drive growth — Source | Via News | es.VIA.NEWS